Table 1.
Baseline characteristics according to relapse status.
| No relapse | Relapse | ||
|---|---|---|---|
| N = 51 | N = 18 | ||
| Sex (F/M) | F | 41 (80%) | 15 (83%) |
| M | 10 (20%) | 3 (17%) | |
| Age (years) | 51 ± 13 | 47± 13 | |
| BMI (kg/m2) | 24 ± 4.2 | 23 ± 2.8 | |
| Treatment time (months) | 20 (18–22) | 19 (18–21) | |
| Follow-up after ATD withdrawal (months) | 11 (3.9–28) | 1 (0.5–12) | |
| Thyroid volume by sonography (mL) | 14 (11–16) | 15 (9.8–17) | |
| Goiter size (struma grade, 0-III) | 0 | 24 (56%) | 9 (60%) |
| I | 10 (23%) | 5 (33%) | |
| II | 8 (19%) | 1 (7%) | |
| III | 1 (2%) | 0 (0%) | |
| Missing | 8 | 3 | |
| Orbitopathy | 13 (25%) | 7 (39%) | |
| Smoking | 8 (16%) | 1 (6%) | |
| fT4 (pM) | 30 (21–36) | 38 (21–55) | |
| T3 (pM) | 3.5 (2.3–4.3) | 2.9 (2.8–7.1) | |
| TPO-AK (U/L) | 91 (34–454) | 163 (90–357) | |
| TRAb (U/L) | 5.2 (2.6–11) | 12 (3.5–27) | |
| Additional autoimmune diseases | GIT (IBD, celiac disease, pernicious anemia) | 1 | 1 |
| Type I Diabetes mellitus | 1 | 0 | |
| Other | 1 | 0 |
Data presented as counts (percentages), mean (± standard deviation), or median (interquartile range). ATD, anti-thyroid drugs; GIT, gastrointestinal tract; IBD, inflammatory bowel disease; pM, pmol/L.